Search

Displaying results 4101 - 4110 of 4297 in total
  1. Drug

    BZL101

    go.drugbank.com/drugs/DB05051
    Investigational

    BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.

  2. Drug

    Lintitript

    go.drugbank.com/drugs/DB04867
    Experimental

    Lintitript is a new, highly specific and potent CCK-A receptor antagonist.

  3. Drug

    BACTEK-R

    go.drugbank.com/drugs/DB16526
    Investigational

    MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. These include streptococcus pneumoniae and staphylococcus aureus. Though stud...

  4. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  5. Drug

    Nitroxoline

    go.drugbank.com/drugs/DB01422
    Experimental

    Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs. Nitrox...

  6. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

  7. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.

  8. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).

  9. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.

  10. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653].